Agilon Health, Inc. Q1 FY2026 earnings call

Ronald Williams mentioned in 2026 the focus on disciplined execution and building a durable foundation. In 2025, meaningful progress was made, and Tim O'Rourke joined as new CEO. First quarter results were above expectations with operational discipline. Key initiatives include enhanced data pipeline, clinical and quality programs (congestive heart failure program scaled, COPD and dementia programs being rolled out), quality and STARS performance, and ACO REACH. The enhanced data pipeline provides more timely data, enabling quicker identification and improvement. Clinical programs like CHF show positive trends, and plans to scale COPD and dementia pathways. Quality performance is a result of integrated model, and ACO REACH demonstrates strength. Jeffrey Alan Schwaneke discussed financial performance, cost and macroeconomic trends, and revised full-year 2026 outlook. First quarter exceeded guidance, driven by strategic actions, and revised revenue, medical margin, and adjusted EBITDA expectations. Balance sheet had cash and marketable securities, and reverse stock split occurred

In the first quarter, revenue was approximately $1.42 billion compared to $1.53 billion in the same period of 2025. Medical margin for the first quarter was $149 million compared to $128 million in 2025. ACO REACH adjusted EBITDA for the first quarter was $27 million. Medicare Advantage membership at the end of the quarter was 426,000, compared to 491,000 in Q1 2025. ACO REACH membership for Q1 was 110,000 members, compared to 114,000 in the same period of 2025. Revenue for the first quarter was driven by higher-than-expected revenue from risk adjustment, an additional full-risk contract, and increased revenue from higher estimated risk scores. Medical expense cost trends for 2025 continue to develop favorably, but there were additional reserves related to Part D costs for 2025. Revised estimate for the increase in risk scores over 2025 for the full year is now 1.5%

Revised full-year 2026 guide reflects strong first quarter results. Expect revenue of approximately $5.7 billion, medical margin of approximately $375 million, and adjusted EBITDA of approximately $25 million. Second quarter expected revenue of $1.45 billion, medical margin of $123 million, and adjusted EBITDA of $20 million. Maintained full-year net cost trend outlook of 7%. Confidence in key tenets like operating execution, data visibility, payer contracting, and conservative cost trend assumption

Q: About ACO REACH EBITDA and AI efficiencies; A: $5 million benefit from 2025 was related to CMS actions, early in year to adjust REACH performance beyond that; AI has limited early impact on OpEx, more on revenue and medical cost.

Q: About scaling clinical programs; A: Scaling of dementia and COPD pathways is ongoing, could add value in 2026 but takes time.

Q: About ACO REACH clients and LEAD program; A: Analyzing LEAD program details, think can be successful in both programs.

Q: About medical margin upside in quarter; A: Variance due to risk adjustment update and new contract.

Q: About geography entry expenses and cost trend; A: Geo entry expenses in line with expectations, 7.4% cost trend in Q1 due to limited paid claims visibility.

Q: About payer bids and MA mix; A: Payers focus on margin improvement, group MA mix unchanged.

Q: About upside in quarter and 2027 confidence; A: Upside from risk adjustment update, more confidence for 2027.

Q: About new full-risk contract; A: In existing market with physician group, modeled as breakeven margin for year.

Q: About unlinked chart reviews and CMS impact; A: Feel good about position, focus on linked documentation.

Q: About LEAD model and payer incentives; A: Little info on AI-inferred risk model, payer incentives opportunity doubled.

Q: About growing member base; A: Focus on in-market growth and execution now, time to expand later